Q4 2018 Earnings Estimate for Integra Lifesciences Holdings Corp Issued By Oppenheimer (IART)

Integra Lifesciences Holdings Corp (NASDAQ:IART) – Research analysts at Oppenheimer dropped their Q4 2018 earnings estimates for shares of Integra Lifesciences in a report issued on Thursday, November 1st. Oppenheimer analyst S. Lichtman now anticipates that the life sciences company will post earnings per share of $0.62 for the quarter, down from their prior forecast of $0.63. Oppenheimer currently has a “Buy” rating and a $70.00 target price on the stock.

Other analysts have also recently issued reports about the company. Cantor Fitzgerald reissued a “hold” rating and set a $59.00 target price on shares of Integra Lifesciences in a research note on Wednesday, July 25th. Zacks Investment Research raised Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. BidaskClub cut Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Friday, July 27th. BTIG Research raised Integra Lifesciences from a “neutral” rating to a “buy” rating and set a $69.00 target price for the company in a research note on Thursday, July 26th. Finally, Bank of America cut Integra Lifesciences from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 7th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $61.00.

Shares of NASDAQ:IART opened at $53.66 on Monday. Integra Lifesciences has a fifty-two week low of $45.96 and a fifty-two week high of $67.50. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.27 and a current ratio of 3.52. The company has a market capitalization of $4.57 billion, a P/E ratio of 27.66, a PEG ratio of 1.66 and a beta of 0.76.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.59. The business had revenue of $365.85 million for the quarter, compared to the consensus estimate of $367.89 million. Integra Lifesciences had a net margin of 5.49% and a return on equity of 18.01%. Integra Lifesciences’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the company posted $0.45 EPS.

In other news, VP Glenn Coleman sold 8,916 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $63.00, for a total transaction of $561,708.00. Following the completion of the transaction, the vice president now directly owns 16,795 shares of the company’s stock, valued at approximately $1,058,085. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeffrey Mosebrook sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, August 10th. The stock was sold at an average price of $62.42, for a total transaction of $62,420.00. Following the transaction, the insider now directly owns 3,085 shares of the company’s stock, valued at $192,565.70. The disclosure for this sale can be found here. Insiders have sold a total of 56,592 shares of company stock valued at $3,573,584 over the last ninety days. Company insiders own 5.10% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Zions Bancorporation bought a new position in shares of Integra Lifesciences during the 3rd quarter worth approximately $272,000. Victory Capital Management Inc. acquired a new stake in shares of Integra Lifesciences in the 3rd quarter valued at approximately $4,155,000. State Board of Administration of Florida Retirement System boosted its holdings in shares of Integra Lifesciences by 2.2% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 73,754 shares of the life sciences company’s stock valued at $4,858,000 after buying an additional 1,579 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in shares of Integra Lifesciences by 6,993.4% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 27,806 shares of the life sciences company’s stock valued at $1,832,000 after buying an additional 27,414 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in shares of Integra Lifesciences by 2.4% in the 3rd quarter. Arizona State Retirement System now owns 50,172 shares of the life sciences company’s stock valued at $3,305,000 after buying an additional 1,196 shares during the last quarter. 84.33% of the stock is owned by institutional investors.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: What is the Dividend Aristocrat Index?

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply